# Clinical Trial to Evaluate the Efficacy and Safety of Suvaro®OD Tablet in Patients With Dyslipidemia

Study · id `cardio:ct-nct06153433` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06153433](<https://clinicaltrials.gov/study/NCT06153433>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT06153433

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 112 participants.

## Technical summary

Registry record NCT06153433. Randomized; no masking; primary purpose treatment. Start 2023-11-06 (actual); primary completion 2024-07 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 112 participants (planned count; ClinicalTrials.gov record NCT06153433, source copy `cardio:ctgov-nct06153433-2023-12-01`, retrieved 2026-10-31)
- Started: 2023-11-06 (actual) (ClinicalTrials.gov record NCT06153433, source copy `cardio:ctgov-nct06153433-2023-12-01`, retrieved 2026-10-31)
- Primary completion: 2024-07 (anticipated) (ClinicalTrials.gov record NCT06153433, source copy `cardio:ctgov-nct06153433-2023-12-01`, retrieved 2026-10-31)
- Completion: 2024-08 (anticipated) (ClinicalTrials.gov record NCT06153433, source copy `cardio:ctgov-nct06153433-2023-12-01`, retrieved 2026-10-31)
- Countries: South Korea (ClinicalTrials.gov record NCT06153433, source copy `cardio:ctgov-nct06153433-2023-12-01`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06153433-2023-12-01`, retrieved 2026-10-31)

## The registry's words

- Brief title: Clinical Trial to Evaluate the Efficacy and Safety of Suvaro®OD Tablet in Patients With Dyslipidemia
- Condition: Dyslipidemia
- Intervention (Drug): Rosuvastatin Immediate-Release Tablet (IRT) 10mg
- Intervention (Drug): Rosuvastatin orally disintegrating tablet (SUVARO®ODT) 10mg
- Lead sponsor: Yonsei University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry lists this organization as the lead sponsor: Yonsei University (`cardio:org-yonsei-university`)

## Provenance

Content hash: de004041c0992297c1ffaa756e6bafa826b9f710363f886f8f8cb9b57bba3d55
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
